Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Scribe Therapeutics Inc.

SCTXNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Jul 29, 2026Accepted Jul 29, 2026, 6:47 PM EDTFiling CIK 1853921Accession 0000947871-26-000733
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-07-27
Issuer
Scribe Therapeutics, Inc.
Issuer CIK
0001853921
Trading symbol
SCTX

Reporting owner 1

Name
ORBIMED ADVISORS LLC
Reporting owner CIK
0001055951
Relationship
Director
Address
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK, NY, 10022

Reporting owner 2

Name
OrbiMed Capital GP VIII LLC
Reporting owner CIK
0001845804
Relationship
Director
Address
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK, NY, 10022-4629

Non-derivative transactions

Non-derivative transactions · 2 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnershipNature of ownership
Common Stock2026-07-27C · Form 4348,825A[F1]348,825ISee footnotes[F3][F4]
Common Stock2026-07-27P · Form 41,000,000[F2]A151,348,825ISee footnotes[F3][F4]
Table key
C · Form 4
Derivative conversion
A
Acquired
I
Indirect
P · Form 4
Purchase on the market or privately

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnershipNature of ownership
Series B Preferred Stock[F1]2026-07-27C · Form 42,065,672D0[F1][F1]Common Stock348,8250ISee footnotes[F3][F4]
Table key
C · Form 4
Derivative conversion
D
Disposed
I
Indirect

Footnotes

F1
Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.↩ 1↩ 2↩ 3↩ 4
F2
Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.↩ 1
F3
The shares are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.↩ 1↩ 2↩ 3
F4
This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.↩ 1↩ 2↩ 3

Signature 1

Signed
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Date
2026-07-29

Signature 2

Signed
/s/ Carl L. Gordon, Member of OrbiMed Capital GP VIII LLC
Date
2026-07-29

Company context

We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions. By targeting prevalent diseases with significant unmet need and high clinical burden, we aim to usher in a new era of broadly scalable, transformative, and preventative genetic medicines. Our focus is on cardiovascular and metabolic diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease, or ASCVD. We are designing CRISPR-based genetic medicines to be well-tolerated, effective, durable, and scalable enough to shift the treatment paradigm from symptom-driven intervention and chronic care to population-level prevention, with the goal of broadly democratizing access to the cardioprotective effects of known genetic variants. Our lead product candidate, STX-1150, utilizes ELXR, our highly engineered epigenetic silencing technology, and is designed to deliver persistent and potent LDL-C reductions without permanent genetic changes. STX-1150 is a demonstration of moving towards our goal to transform practical therapeutic adherence and real-world medical outcomes for patients in the multibillion-dollar LDL-C lowering landscape. We have secured regulatory clearance from the Australian Therapeu

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by AH Bio Fund II, L.P. regarding Scribe Therapeutics, Inc.Nov 16, 2026
  2. 10-Q filingNov 12, 2026
  3. Results of Operations and Financial ConditionNov 12, 2026
  4. 10-Q filingSep 2, 2026
  5. Results of Operations and Financial ConditionSep 2, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.